# Molecular Oncology Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $87,279

## Abstract

Experimental Therapeutics Program: Summary 
The overarching mission of the Experimental Therapeutics (ET) Program is to discover and validate 
therapeutic targets and subsequently identify, develop, and test novel therapeutic strategies and biomarkers. 
The close collaboration between discovery scientists and clinicians allows a multifaceted assessment of 
therapeutic strategies in iterative cycles from bench to bedside. Discoveries within the rich scientific 
environment of the HDFCCC have resulted in the development of a large number of biotech start-ups, and the 
movement of discoveries into the private sector for clinical implementation. Most often, this takes the form of 
early biotech start-ups launched by UCSF faculty. Thus, this discovery cycle can also include `bench to 
boardroom,' since the lengthy arc from initial discovery to clinical approval and adoption requires industrial 
participation ranging from early biotech start-ups to pharmaceutical companies. Genomic and molecular 
imaging target validation are a central clinical focus of the ET Program. Promising clinical translational 
strategies are tested in the HDFCCC Early Phase Clinical Trials Unit. In addition to facilitating translation of 
science from its members, the ET Program serves as a clinical translational hub for the entire HDFCCC, since 
all clinical investigators in the ET Program participate in disease-specific Site Committees. These investigators 
consequently serve as a two-way conduit of collaborative interactions between the Site Committees and the 
ET Program. Research in the ET Program is conducted under two cross-cutting themes: 
Theme 1: Targeting Signal Transduction in Cancer 
Theme 2: Targeting Epigenetic Modulation, Cellular Homeostasis, and the Tumor Environment

## Key facts

- **NIH application ID:** 10406950
- **Project number:** 5P30CA082103-23
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Pamela N. Munster
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $87,279
- **Award type:** 5
- **Project period:** 1999-08-05 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10406950

## Citation

> US National Institutes of Health, RePORTER application 10406950, Molecular Oncology Program (5P30CA082103-23). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10406950. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*